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Abstract 
Background: Cancer cells are typically surrounded by stromal cells and embedded in extracellular matrix (ECM). 
The stromal compartment interacts with cancer cells to promote growth and metastasis. For decades, autologous 
fasciocutaneous flaps have been safely applied for breast reconstruction after mastectomy. In contrast, the safety of 
fat grafting (lipofilling) procedure has been under debate regarding the risk of cancer recurrence.
Methods: Harvested fat tissue (lipoaspirates) and dissected abdominal fat (DAF) were co‑cultured with MCF‑7 breast 
cancer cells. The vitality of MCF‑7 cells was measured using AlamarBlue® consecutively for 5 days. ECM degradation 
was determined by detection of matrix metalloproteinase‑1 (MMP‑1) expression in MCF‑7 cells. Integrin α2 was meas‑
ured by Western blot to assess the degree of adhesion and motility of MFC‑7 cells.
Results: The MCF‑7 proliferation increased substantially when co‑cultured with fat tissue. However, there was no 
significant difference between the proliferation stimulating effects of lipoaspirates and DAF. Similarly, MMP‑1 protein 
expression was equally elevated in MCF‑7 cells by both lipoaspirates and DAF. Importantly, MCF‑7 cells showed an 
increased level of integrin α2 once co‑cultured with either lipoaspirates or DAF.
Conclusion: Fat tissue increases the proliferation of MCF‑7 cells in vitro. Our data suggest that lipoaspirates as well as 
DAF might possess a considerable potency to promote tumorigenic growth of breast cancer cells. Thus, clinical trials 
are needed to address the safety of lipofilling by breast reconstruction surgery after mastectomy.
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Background
Cancer cells are typically surrounded by stromal cells like 
mesenchymal, inflammatory and vascular cells. Stromal 
cells support cancer cells by providing mediators for cell 
proliferation, inflammation and angiogenesis [1]. In addi-
tion, cancer cells are embedded in extracellular matrix 
(ECM), which plays crucial roles in modulation of stro-
mal compartment and cancer cell invasion. Modulation 
of the stromal compartment is exerted by matrix metal-
loproteinases (MMPs) [2]. MMPs are involved in many 
physiological and pathological processes in the human 
body, which are normally present in tissues at low lev-
els and increase dramatically during any changes [3, 
4]. Overexpression and activation of MMPs have been 
implicated in pathological cleavage of connective tissue 
by arthritis [5], cardiovascular disease [6], and tumor 
progression [7]. However, the process of metastases is 
complex. In order to migrate, cell adhesion and motility 
molecules are required, after cleavage of the connective 
tissue, to interact with ECM as well as vascular endothe-
lium to the secondary site [8, 9]. Integrin is a family of 
transmembrane receptors consist of α and β subunits and 
serves as cell–cell as well as cell–matrix adhesion mole-
cule [10]. In normal and tumor cells, integrins have a cen-
tral function in intracellular signaling pathways that lead 
to cell proliferation, differentiation and migration [11].
After initial breast cancer surgery like mastectomy or 
breast conserving surgery and subsequent oncological 
therapy, up to 95.5% of these women are considered for 
breast reconstruction including prosthetic implants and 
flaps [12]. The latter represents a wide variety of options 
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as a regional flap, and muscle-sparing Transvers Rectus 
Abdominis Myocutaneous flap “msTRAM” as a free tis-
sue transfer [14]. The Deep Inferior Epigastric artery Per-
forator flap ‘DIEP’ from the abdominal wall has also been 
successfully applied for breast reconstruction [15]. DIEP 
flaps provide a homogenous rounded breast and are cur-
rently considered as a safe procedure in the oncological 
aspect and referred to as the “gold standard” by many 
authors [15, 16].
Since the initial report [17] in 1987, autologous graft-
ing of suspended adipose tissue (lipofilling) has become 
increasingly popular for cosmetic purposes and breast 
reconstruction worldwide. Concurrently, the Ameri-
can Society of Plastic Surgeons (ASPS) criticized this 
method of fat grafting that can compromise breast can-
cer detection [18]. Nowadays, many plastic surgeons 
question the safety of the procedure as well, discuss 
the amount of fat tissue reabsorption and doubt the 
screening results because of micro-calcification [19]. 
Ultimately, it remains unknown whether autologous fat 
grafting enhances the breast cancer recurrence or even 
initiates it at the first place. Adipose tissue and impor-
tantly lipoaspirates is a rich source of growth factors, 
like basic fibroblast growth factor (bFGF), insulin-like 
growth factor 1 (IGF-1), vascular endothelial growth fac-
tor (VEGF), and platelet-derived growth factor (PDGF-
BB) [20]. Besides, mature adipocytes are able to produce 
considerable amounts of estrogen via aromatase-medi-
ated conversion of androgen to estrogen. All these 
factors are able to potentiate the growth of breast car-
cinoma cells through a paracrine mechanism [21–24]. 
Indeed, obesity and weight gain in adult females cor-
relate with an increasing risk of breast cancer [25]. Yet, 
it remains unclear whether dissected abdominal fat ’en 
bloc’ (DAF) and suspended adipose cells like lipoaspi-
rates differ in their abilities to stimulate tumor growth 
and invasion.
Within this study, we observed and compared the 
effects of harvested fat (lipoaspirates) and DAF on breast 
cancer cells in vitro. We measured the proliferation of the 
human breast cancer cells line MCF-7 co-cultured with 
lipoaspirates or DAF. MMP-1 and integrin α2 expression 
of tumor cells were also detected in both circumstances.
Methods
All surgical procedures took place in the Department 
of Plastic Surgery, Hand Surgery, and Burn Center at 
RWTH University Hospital, Aachen, Germany. Each 
patient signed the consent form. The protocol and the 
use of human materials were approved by the ethics com-
mittee of the Faculty of Medicine at RWTH University in 
Aachen, Germany (Name in German: Ethik-Kommission 
des Universitätsklinikums Aachen, Votum Number: 
EK206/13). The experiments were carried out in compli-
ance with Declaration of Helsinki in its current form.
Study design
We selected 8 healthy female patients (n  =  8) who 
underwent elective abdominoplasty and liposuction. 
The ages of the patients were between 25 and 64  years 
(mean  =  46.75  years). The Body Mass Index (BMI) 
was between 24 and 45 (mean  =  32). All lipoaspirates 
included in this study have been harvested only from 
the abdominal wall, and each sample was processed as 
described by Coleman [26]. The lipoaspirates was divided 
into 250  mg samples. Simultaneously, 250  mg fat tis-
sue (en bloc) from the same patient was dissected from 
abdominal fat (DAF). Each lipoaspirates or DAF sample 
was placed into an insert with a 0.4 µm pore size mem-
brane [Thermo Fisher Scientific Inc., USA]. The inserts 
were placed in 6-well plate containing 1.5 × 104 adherent 
MCF-7 breast cancer cells per well. Control wells were 
cultured without addition of fat tissue. Two sets of paral-
lel experiments were performed using 1 or 10% fetal calf 
serum (FCS) (Fig. 1).
Cell culture
The human breast cancer cell line MCF-7 was obtained 
from the American Type Culture Collection [HTB 22; 
derived from a breast adenocarcinoma of 69-year-old 
Caucasian woman]. MCF-7 cells were maintained in 
RPMI 1640 supplemented with 5 ml of Minimal Essential 
Medium non-essential amino acids (NEAA) [PAA, Linz, 
Austria], 1  mM sodium pyruvate [PAA, Linz, Austria], 
1% penicillin and 1% streptomycin [PAA, Linz, Austria], 
10 µg/ml human insulin [Biochrom AG, Berlin, German], 
and 1 or 10% FCS [PAA, Linz, Austria]. Cells were cul-
tured at 37 °C in a humidified atmosphere of 5% CO2.
Proliferation assay
Proliferation of MCF-7 cells was daily monitored using 
AlamarBlue® dye [Life technologies]. This dye is a redox 
indicator that yields a colorimetric change and a fluo-
rescent signal in response to metabolic activity of cells. 
The inserts holding fat tissue samples were removed 
before the assay and kept in pre-warmed medium. The 
MCF-7 culture medium was adjusted to 1  ml in each 
well and 100  µl of the AlamarBlue® reagent was added 
to each well. MCF-7 cell were incubated at 37  °C and 
5% CO2 for 2 h and subjected to fluorescence measure-
ment. After data collection, the reagent was replaced 
by fresh medium and the inserts with fat tissue samples 
were placed back to the corresponding well of MCF-7 
cells. After 5  days, cells were harvested and all samples 
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(medium, fat tissue and cell lysates) were kept by −80 °C 
for further analysis.
Elisa
Matrix metalloproteinase-1 expression in MCF-7 cells 
was measured using an ELISA kit according to the man-
ufacturer’s instructions and in two parallel independent 
experiments [Human Total MMP-1 DuoSet “DY901”, 
R&D Systems, Minneapolis, MN, USA]. The obtained 
data were normalized to the total protein concentration. 
Mean value of the two independent experiments is pre-
sented in corresponding figures in this study.
Western blot
Integrin α2 expression in MCF-7 cells was detected by 
Anti-Integrin α2 antibodies using Western blot accord-
ing to the manufacturer’s instructions and in two parallel 
independent experiments [Anti-Integrin alpha 2 anti-
body (EPR5789), Abcam plc, Cambridge, UK]. Blots were 
detected with the LAS-3000 image analyzer (Fujifilm) 
and protein bands were quantified densitometrically 
using AIDA software (raytest). Relative protein levels 
were obtained by normalization to Tubulin. Mean value 
of the two independent experiments is presented in cor-
responding figures in this study.
Statistical analysis
Values are expressed as the arithmetic mean ± standard 
error of mean (SEM). All assays were performed in dupli-
cate at two different times. The statistical significance of 
differences between groups in the proliferation assay was 
determined via linear regression, whereas significance 
of MMP-1 and Integrin α2 expression was measured by 
t test. The differences were considered statistically sig-
nificant when p < 0.05. All the analyses were performed 




To determine the effect of co-cultured fat tissue on the 
proliferation of breast cancer cells, we harvested fat tis-
sue from various patients by two different techniques, 
liposuction or dissection from the skin flap. MCF-7 
breast cancer cells were cultured with the equal amounts 
of harvested fat tissue or without as control. We used 
Fig. 1 The result after Abdominoplasty and liposuction is a subcutaneous fat from the resected skin flap left and lipoaspirates from liposuction 
right. Each fat sample was adjusted to 250 mg and placed into an insert with a membrane. The inserts were placed in 6‑well plate containing 
1.5 × 104 adherent cancer cells. 2‑well were used for a medium with 10% FCS and other 2‑well for 1% FCS. The last 2‑well was left unused
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AlamarBlue® assay to quantitatively monitor the prolif-
eration of MCF-7 cells. The relative proliferation rates 
of MCF-7 cells were determined by comparison of their 
metabolic activity with or without supplemented fat tis-
sue every 24 h for 5 consecutive days. The data are sum-
marized in Fig.  2a–d and show a significant increase in 
viability of MCF-7 cells when co-cultured with lipoaspi-
rates or DAF compared to the controls lacking fat tis-
sue. Most importantly, there is no significant difference 
between the effects of DAF and lipoaspirates on relative 
MCF-7 proliferation rates (Fig.  3). This has been con-
firmed for 8 different female patients aged between 25 
and 64 year old and with a BMI between 24 and 45.
Expression of MMP‑1
Cell invasion is essential in metastasis of tumors. It 
involves migration of cancer cells through an extracellu-
lar matrix (EMC) or basement membrane extract (BME) 
by enzymatic degradation of these barriers. Matrix met-
alloproteinase-1 (MMP-1) is a crucial proteinase that reg-
ulates cell invasion directly by modeling and remodeling 
of the extracellular matrix. We measured MMP-1 protein 
expression using a direct ELISA test to evaluate the inva-
sion potential of MCF-7 cells with or without co-culture 
Fig. 2 a Demonstrates a significant increase of the relative proliferation of MCF‑7 co‑cultured with DAF comparing to MCF‑7 cells alone (control 
group) in RPMI 1640 medium with 10% FCS; and in 1% FCS (b); c, d Show the difference in relative proliferation between MCF‑7 co‑cultured with 
lipoaspirates and control MCF‑7 in 10 and 1% FCS consequently. Linear regression
Fig. 3 a Demonstrates no statistically difference in the relative 
proliferation between MCF‑7 co‑cultured with DAF and lipoaspirates 
in 10% FCS; and b in 1% FCS. Linear regression
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of fat tissue (lipoaspirates or DAF). MCF-7 cells are gen-
erally recognized as a non-invasive cell line. Thus, our 
data show no or undetectable level of MMP-1 protein 
in total extract from MCF-7 cells. Co-cultivation of fat 
tissue either lipoaspirates or DAF express a significant 
increase of MMP-1 levels (Fig.  4a, b). In the matter of 
comparison between lipoaspirates and DAF co-cultured 
cancer cells, we found no statistical difference (Fig.  4c). 
However, in hunger (1% FCS) medium, we noticed higher 
existence of MMP-1 comparing to normally saturated 
(10% FCS) medium.
Expression of integrin α2
We measured the Integrin α2 to assess the ability of 
MCF-7 cells to bind and interact with the surrounding 
environment in order to migrate. Co-cultured MCF-7 cells 
expressed higher level of Integrin α2 regardless to the type 
of fat tissue (DAF or lipoaspirates) than control groups 
(Figs. 5 and 6). This finding has been observed in medium, 
10 and 1% FCS; however, in latter medium, the Integrin α2 
was expressed in lower levels compared to the former one. 
Discussion
Major achievements have been made in breast recon-
struction following mastectomy surgery. The standard 
of care to reconstruct the breast has focused on tissue 
expander/implants and the use of flaps [27]. Although 
Fig. 4 ELISA levels of MMP‑1 in MCF‑7 lysates after 5 days of co‑cultivation: a MCF‑7 co‑cultured with DAF as well as lipoaspirates in RPMI 1640 
medium with 10% FCS shows marked increase in MMP‑1 levels; b MCF‑7 co‑cultured with DAF as well as lipoaspirates in RPMI 1640 medium with 
1% FCS; c comparison between co‑cultured MCF‑7 with DAF and lipoaspirates in 10 and 1% FCS reveal no significance.  T test
Fig. 5 Densitometrically quantified relative Integrin α2 levels after normalizion to tubulin in MCF‑7 Lysates after 5 days of co‑cultivation: a levels of 
Integrin α2/tubulin are raised in co‑cultured MCF‑7 with DAF as well as lipoaspirates in RPMI 1640 medium with 10% FCS; and with 1% FCS (b); c 
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Fig. 6 Western blot analysis confirming the expressions of Integrin 
alpha2 proteins, and Tubulin proteins in MCF‑7 cells, with and 
without combination of DAF or lipoaspirates. Western blotting was 
performed using the anti‑integrin alpha2 antibody. The molecular 
weights are shown on the left
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often very effective in restoring the contour of the breast, 
both procedures are not without complications. Donor 
site morbidity is a major issue in flap procedures [28]. 
Capsule formation after prosthetic implants and radi-
otherapy-induced complications are still challenging 
[29, 30]. In general, autologous methods are favorable in 
terms of long-term stability of results. However, patient 
safety must have priority in choosing the method of 
reconstruction.
Fat grafting has become frequently used for breast 
reconstruction after mastectomy [31]. Petit et  al. con-
cluded in a multicenter study that lipofilling of the breast 
is a safe procedure after most oncological breast surger-
ies [32]. In contrast, Yu et al. demonstrated in an animal 
model, that co-injection of adipocytes-derived stem cells 
(ASCs) promote proliferation of tumor cells [33]. Further-
more, several other studies described the effect of stro-
mal cells on tumorigenesis in terms of cancer survival, 
proliferation, invasion, and migration [34]. In this study, 
we report that lipoaspirates significantly increase prolif-
eration of human MCF-7 breast cancer cells in  vitro. It 
is well known that adipocytes contain a variety of tumor 
promoting factors, even in estrogen-negative cells, like 
adiponectin, leptin, collagen IV, and hepatocytes growth 
factor [35–38]. Therefore, not only ASCs enhance tumor 
growth but also adipocytes as contained in lipoaspirates 
may stimulate tumor growth. Tumor invasion is a hall-
mark of malignant tumors. The ability of tumor cells to 
degrade the ECM indicates the invasion potential of these 
cells and subsequently migration and metastasis [7, 39]. 
We detected a significant increase in MMP-1 expression 
in MCF-7 cells when co-cultured with lipoaspirates. In 
comparison, MMP-1 was not detectable in control groups 
(non-co-cultured). Interestingly, MMP-1 showed higher 
existence in hunger medium (1% FCS) than in saturated 
medium (10% FCS), which may suggest the higher ten-
dency to invade the ECM under the former medium. 
Tumor metastasis to secondary sites demands cell motil-
ity as well as interactions between tumor cells and the 
microenvironment. As binding molecule, Integrin α2β1 
has shown high expression in tumor cells isolated from 
secondary sites [40–43]. In our study, the expression of 
Integrin α2 in Western blot was significantly higher in 
lipoaspirates-co-cultured MCF-7 cells than the control 
groups. Riikonen et  al. reported an association between 
Integrin α2β1 and regulation of MMP-1 expression [44]. 
In their findings, the increase of Integrin α2 levels was 
positively associated with an elevation of MMP-1 expres-
sion. In our study, we could also demonstrate an increase 
in Integrin α2 levels accompanied with upregulated 
MMP-1 expression. However, this effect was differentially 
regulated with higher Integrin α2 levels resulting in only 
moderate increase of MMP-1 expression over controls. 
The exact role of different levels of Integrin α2 overex-
pression is still controversial [45–47].
Apart from lipofilling, DIEP flap is considered as the 
gold standard procedure to reconstruct the breast espe-
cially in Europe [48]. DIEP flap contains fat cells in their 
regular texture and tissue composition. Our study dem-
onstrates for the first time the impact of adipose tissue 
‘en bloc’ as a small subunit of the DIEP flap on breast 
cancer cells. We have reported a significant increase in 
proliferation of DAF-co-cultured MCF-7 cells than non-
co-cultured cells. Interestingly, it showed statistically no 
difference between the proliferation of MCF-7 cells co-
cultured with DAF or lipoaspirates. Furthermore, the 
level of MMP-1 in MCF-7 cells was equally elevated by 
addition of DAF or lipoaspirates. MMP-1 demonstrates 
not only the invasive activity of cells through degrada-
tion of the ECM, but also has a crucial role in the pro-
cess of metastasis through intercellular signaling [39]. 
Moreover, the expression of Integrin α2 was significantly 
increased in DAF-co-cultured MCF-7 cells but with no 
difference to cells co-cultured with lipoaspirates. This 
indicates the stimulation of the carcinogenic growth and 
migration potential of MCF-7 cells by exposure to either 
forms of fat tissue. However, we cannot rule out that 
MCF-7 cells in co-culture with fat tissue may induce an 
increase of MMP-1 expression in the fat tissue itself. Gao 
and Bing reported that MMP-1 is expressed and secreted 
by preadipocytes and to a much lesser extent in mature 
adipocytes, but can be stimulated by macrophage-condi-
tioned medium in both cells types [49].
Proliferation, invasion, and migration are all differ-
ent pathological behaviors of cancer cells. Ultimately, 
DAF and lipoaspirates exhibit an equal enhancement 
of these behaviors on breast cancer cells (MCF-7). It is 
known that stromal vascular fraction and mature adi-
pocytes share about 60% of their proteome [50]. There-
fore, we could understand the tumorigenic effect of DAF 
and lipoaspirates as well. Before identification of ASCs, 
obesity was linked to breast cancer in postmenopausal 
women. Both, the risk and the rate of mortality by breast 
cancer have been associated with obesity in several stud-
ies [51–55]. Over weight has been shown to affect the 
prognosis through enhancing the metastasis rate and 
resistance to drugs [56, 57]. Moreover, abdominal obesity 
and breast cancer were strongly linked in several studies 
[58, 59]. While ASCs are not the only player in stimula-
tion of tumorigenic growth, the presence of adipocytes 
have also increased the carcinogenicity as contained in a 
flap or suspended in lipoaspirates.
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Conclusion
Approximately 80–100% of breast cancer recurrences 
occur at the tumor bed in the first 3–5  years after ini-
tial treatment. Thus, local residing cancer cells and the 
elimination of recurrence risk will remain the main con-
cerns in reconstructive surgery after mastectomy. Our 
study addresses the tumorigenic growth of human breast 
cancer cells by fat tissue transfer in  vitro. Independent 
of harvesting procedure, fat tissue obviously bears the 
potency to enhance tumorigenic growth activity of can-
cer cells in  vitro. Notably, autologous flaps have been 
applied without remarkable oncologic complications for 
many years in vivo. It remains to be investigated whether 
lipofilling triggers any oncologic diseases in healthy 
patients. Therefore it seems warranted to assess the can-
cer recurrence risks and the safety of reconstructive sur-
gery in extended clinical studies in the future.
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